Clinical Trials Logo

Peritonitis clinical trials

View clinical trials related to Peritonitis.

Filter by:

NCT ID: NCT05850858 Recruiting - Clinical trials for Cirrhotic Patients With Spontaneous Bacterial Peritonitis

Platelets to Lymphocytes Ratio and Monocytes to Lymphocytes Ratio as Predictors of Response to Treatment in Cirrhotic Patients With Spontaneous Bacterial Peritonitis.

Start date: April 19, 2023
Phase:
Study type: Observational

Spontaneous bacterial peritonitis (SBP) is a serious complication of ascites that can lead to death and can be described as an acute infection of ascites without any certain source of infection SBP is considered the most common infection in cirrhotic patients with ascites. SBP is diagnosed by the presence of ≥250 polymorphonuclear leukocyte (PMNL)/mm3 in the ascetic fluid in absence of surgical and treatable causes of intra-abdominal infections . SBP has many pictures of clinical presentation SBP can be asymptomatic and patients pass unnoticed or can discovered accidentally may have local symptoms and signs of peritonitis such as abdominal pain, and tachypnea or may present with signs of deteriorated liver function in form of gastrointestinal bleeding, shock and renal failure An increasing amount of studies have demonstrated that peripheral blood neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR) are indicators of systematic inflammatory response and are widely investigated as useful predictors of the clinical outcomes in various diseases .

NCT ID: NCT05840419 Completed - Surgery Clinical Trials

Retrospective Comparison Between AirSeal® and Standard Insufflation in Appendicular Peritonitis

APPAS
Start date: January 1, 2022
Phase:
Study type: Observational

The AirSeal System Valve-less Trocar is known to decrease postoperative pain, consumption of analgesics, operating time, and length of stay in adults during robotic and laparoscopic procedures. The investigators would like to know if these allegations also apply to children.

NCT ID: NCT05696054 Not yet recruiting - Clinical trials for Spontaneous Bacterial Peritonitis

Laboratory Diagnosis of Spontaneous Bacterial Peritonitis

SBP
Start date: February 15, 2023
Phase:
Study type: Observational

This study aims at evaluating the diagnostic accuracy of serum procalcitonin, PEC index, modified Wehmeyer, and Mansoura scoring systems for SBP in cirrhotic patients with ascites

NCT ID: NCT05684198 Recruiting - Clinical trials for Surgical Site Infection

NPWT vs Primary Closure in SSI Prevention for Emergency Laparotomies for Peritonitis

PRISTINE
Start date: January 11, 2023
Phase: N/A
Study type: Interventional

The study aims to evaluate the efficacy of negative pressure wound therapy (NPWT) compared with primary closure (PC) in surgical site infection (SSI) prevention for laparotomy for peritonitis.

NCT ID: NCT05641792 Not yet recruiting - Hyperglycemia Clinical Trials

Continuous Glucose Monitoring for Emergency Laparotomy

CLUE
Start date: March 15, 2023
Phase: N/A
Study type: Interventional

CLUE trial aims to determine the feasibility and predictive value for surgical site infection (SSI) of continuous glucose monitoring (CGM) in emergency laparotomy patients with diffuse peritonitis.

NCT ID: NCT05621005 Completed - Ascites Infection Clinical Trials

Rifaximin Prophylaxis for Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome in Cirrhotic Patients

Start date: March 1, 2019
Phase: Phase 2
Study type: Interventional

Norfloxacin is the most commonly used drug for the prophylaxis against spontaneous bacterial peritonitis (SBP) in patients with liver cirrhosis. Rifaximin, another broad spectrum antibiotic with only trivial absorption from the gut, is used for the treatment of traveler's diarrhea and prevention of hepatic encephalopathy.

NCT ID: NCT05511766 Recruiting - Cirrhosis Clinical Trials

Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis

Start date: November 15, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

The study aims to compare the potential benefit of allopurinol versus atorvastatin in reducing the risk of developing cirrhosis-related complications, delaying the onset of hepatocellular carcinoma, and improving survival. Furthermore, the study aims to evaluate their impact on parents' related quality of life.

NCT ID: NCT05450523 Completed - Clinical trials for Peritoneal Dialysis-associated Peritonitis

Neutrophil Gelatinase-Associated Lipocalin (NGAL) Rapid Test (Colloidal Gold) Clinical Trial Protocol

Start date: December 28, 2021
Phase:
Study type: Observational

According to the requirements of the "Technical Guidelines for Clinical Trials of In Vitro Diagnostic Reagents", the first registered product (hereinafter referred to as the assessment reagent) - Neutrophil Gelatinase-Associated Lipocalin (NGAL) Rapid Test (Colloidal Gold) was tested in clinical institutions. ) for clinical validation trials. Prove that the clinical performance of the assessment reagent meets the requirements of the intended use.

NCT ID: NCT05427747 Not yet recruiting - Clinical trials for Spontaneous Bacterial Peritonitis

Meropenem vs Cefotaxime as Empirical Treatment of SBP

Start date: January 1, 2023
Phase: Phase 4
Study type: Interventional

We aimed to evaluate whether meropenem is superior to cefotaxime for treatment of SBP empirically.

NCT ID: NCT05422118 Recruiting - Clinical trials for Spontaneous Bacterial Peritonitis

Ascitic Fluid Calprotectin as an Accurate Diagnostic Marker for Spontaneous Bacterial Peritonitis

Start date: June 10, 2022
Phase: N/A
Study type: Interventional

Spontaneous bacterial peritonitis (SBP) is an infection of the ascitic fluid in patients with liver cirrhosis and portal hypertension. There is no obvious surgical cause as perforation or intraabdominal inflammatory focus as abscess. Up to 30% of the ascitic patients will develop SBP. SBP is attributed to immune dysfunction, bacterial translocation, circulatory dysfunction and inflammatory status. SBP is diagnosed by ascitic fluid analysis . SBP was defined as polymorphonuclear leucocyte count (PMN) >250/mm3 in ascitic fluid, . Not all cases are associated with positive ascitic fluid cultures. There are variants of ascitic fluid infections as culture-negative neutrocytic ascites, monomicrobial non-neutrocytic bacterascites, polymicrobial bacterascites and secondary bacterial peritonitis. The advent of the SBP carries a poor prognosis where the hospital mortality ranged from 10 to 50%. As a consequence, any patient with SBP should be assessed for liver transplantation. Immediate treatment with antibiotics and IV albumin should be initiated. Studies were conducted on alternatives of the ascitic PMN count as high sensitivity C-reactive protein (hsCRP), serum procalcitonin, urinary lipocalin, ascitic lactoferrin, homocysteine and fecal or ascitic calprotectin. The gold standard test for SBP is ascitic fluid analysis with measurement of the PMN. It is useful for the diagnosis and monitoring of treatment. The culture of the ascitic fluid may be positive if was done correctly . There is a variant of SBP that is called culture-negative neutrocytic ascites. It is characterized by elevated ascitic fluid PMN but the culture is negative. It is managed exactly as classic SBP. Such cases would be missed if cultures were not done The manual PMN counting is time consuming, laborious and required some experience to avoid intra- and inter-observer variability. So, a simple rapid bedside test would be useful clinically. Calprotectin is acute-phase inflammatory protein that is released from the PMN. Calprotectin has anti-proliferative and antimicrobial properties. Calprotectin is used clinically widespread in the diagnosis and monitoring treatment of inflammatory bowel disease .